The utility of FDG-PET/CT as an effective tool for detecting recurrent colorectal cancer regardless of serum CEA levels

Annals of Nuclear Medicine

Volumn 26, Issue 7, 2012, Pages 551-558

  Sanli, Yasemin ^a   Kuyumcu, Serkan ^a   Ozkan, Zeynep Gozde ^a   Kilic, Leyla ^b   Balik, Emre ^a   Turkmen, Cuneyt ^a   Has, Duygu ^a   Isik, Goknur ^a   Asoglu, Oktar ^a   Kapran, Yersu ^a   Adalet, Isik ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

CEA levels; Colorectal cancer; FDG PET CT; Recurrence

Indexed keywords

ANTINEOPLASTIC AGENT; CARCINOEMBRYONIC ANTIGEN; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; COLON ADENOCARCINOMA; COLORECTAL CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; RECTUM CARCINOMA; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TUMOR BIOPSY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RECURRENCE; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84866736047     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-012-0609-0     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-49.
2. Wei AC, Greig PD, Grant D, Taylor B, Langer B, Gallinger S. Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol. 2006;13:668-76.
3. Simmonds PC, Primrose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer. 2006;10:982-99.
4. Watanabe K, Nagai K, Kobayashi A, Sugito M, Saito N. Factors influencing survival after complete resection of pulmonary metastases from colorectal cancer. Br J Surg. 2009;96:1058-65.
5. Flamen P, Stroobants S, Van Cutsem E, Dupont P, Bormans G, De Vadder N, et al. Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent CRC. J Clin Oncol. 1999;17:894-901.
6. Haier J, Nicolson GL. The role of tumour cell adhesion as an important factor in formation of distant colorectal metastasis. Dis Colon Rectum. 2001;44:876-84.
7. Flamen P, Hoekstra OS, Homans F, Van Cutsem E, Maes A, Stroobants S, et al. Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET). Eur J Cancer. 2001;37:862-9.
8. van der Schouw YT, Verbeek AL, Wobbes T, Segers MF, Thomas CM. Comparison of four serum tumour markers in the diagnosis of colorectal carcinoma. Br J Cancer. 1992;66:148-54.
9. George PK, Loewenstein MS, O'Brien MJ, Bronstein B, Koff RS, Zamcheck N. Circulating CEA levels in patients with fulminant hepatitis. Dig Dis Sci. 1982;27:139-42.
10. Sacks A, Peller PJ, Surasi DS, Chatburn L, Mercier G, Subramaniam RM. Value of PET/CT in the management of liver metastases, part 1. AJR Am J Roentgenol. 2011;197:256-9.
11. Deleau C, Buecher B, Rousseau C, Kraeber-Boderé F, Flamant M, des Varannes SB, et al. Clinical impact of fluorodeoxyglucose-positron emission tomography scan/computed tomography in comparison with computed tomography on the detection of colorectal cancer recurrence. Eur J Gastroenterol Hepatol. 2011;23:275-81.
12. Mittal BR, Senthil R, Kashyap R, Bhattacharya A, Singh B, Kapoor R, et al. 18F-FDG PET/CT in evaluation of postoperative colorectal cancer patients with rising CEA level. Nucl Med Commun. 2011;32:789-93.
13. Votrubova J, Belohlavek O, Jaruskova M, Oliverius M, Lohynska R, Trskova K, et al. The role of FDG PET/CT in the detection of recurrent colorectal cancer. Eur J Nucl Med Mol Imaging. 2006;33:779-84.
14. Tan E, Gouvas N, Nicholls RJ, Ziprin P, Xynos E, Tekkis PP. Diagnostic precision of carcinoembryonic antigen in the detecetion of colorectal cancer. Surg Oncol. 2009;18:15-24.
15. Engarås B. Individual cutoff levels of carcinoembryonic antigen and CA 242 indicate recurrence of colorectal cancer with high sensitivity. Dis Colon Rectum. 2003;46:313-21.
16. McCall JL, Black RB, Rich CA, Harvey JR, Baker RA, Watts JM, et al. The value of serum carcinoembryonic antigen in predicting recurrent disease following curative resection of colorectal cancer. Dis Colon Rectum. 1994;37:875-81.
17. Choi MY, Lee KM, Chung JK, Lee DS, Jeong JM, Park JG, et al. Correlation between serum CEA level and metabolic volume as determined by FDG PET in postoperative patients with recurrent colorectal cancer. Ann Nucl Med. 2005;19:123-9.
18. Ogunbiyi OA, Flanagan FL, Dehdashti F, Siegel BA, Trask DD, Birnbaum EH, et al. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. Ann Surg Oncol. 1997;4:613-20.
19. Kantorová I, Lipská L, Bêlohla'vek O, Visokai V, Trubaĉ M, Schneiderová M. Routine (18)F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making. J Nucl Med. 2003; 44:1784-8.
20. Kim JH, Czermin J, Allen-Auerbach MS, Halpern BS, Fueger BJ, Hecht JR, et al. Comparison between 1-FDG PET, in line PET/ CT, and software fusion for restaging of recurrentcolorectal cancer. J Nucl Med. 2005;46:587-95.
21. Schmidt GP, Baur-Melynk A, Haug A, Utzschneider S, Becker CR, Tiling R, et al. Whole-body MRI at 1.5 T and 3 T compared with FDG PET/CT for the detecetion of tumour recurrence in patients with colorectal cancer. Eur Radiol. 2009;19:1366-78.
22. Fiocchi F, Iotti V, Ligabue G, Malavasi N, Luppi G, Bagni B, et al. Role of carcinoembrynic antigen, magnetic resonance imaging, and positron emisson tomography-computed tomography in the evaluation of patients with suspected local recurrence of colorectal cancer. Clin Imaging. 2011;35:266-73.
23. Arulampalam T, Costa D, Visvikis D, Boulos P, Taylor I, Ell P. The impact of FDG-PET on the management of algorithm for recurrent colorectal cancer. Eur J Nuc Med. 2001;28:1758-65.
24. Maas M, Rutten IJ, Nelemans PJ, Lambregts DM, Cappendijk VC, Beets GL, et al. What is the most accurate whole-body imaging modality for assessment of local and distant recurrent disease in colorectal cancer? A meta-analysis: imaging for recurrent colorectal cancer. Eur J Nucl Med Mol Imaging. 2011;38:1560-71.
25. Shamim SA, Kumar R, Halanaik D, Shandal V, Reddy RM, Bal CS, et al. Role of FDG PET/CT in detection of recurrent disease in colorectal cancer. Nucl Med Commun. 2010;31:590-6.
26. Liu FY, Chen JS, Changchien CR, Yeh CY, Liu SH, Ho KC, et al. Utility of 2-fluoro-2-deoxy-D-glucose positron emission tomography in managing patients of colorectal cancer with unexplained carcinoembryonic antigen elevation at different levels. Dis Colon Rectum. 2005;48:1900-12.
27. Cook GJ, Maisey MN, Fogelman I. Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. Eur J Nucl Med. 1999;26: 1363-78.
28. Kyoto Y, Momose M, Kondo C, Itabashi M, Kameoka S, Kusakabe K. Ability of 18F-FDG PET/CT to diagnose recurrent colorectal cancer in patients with elevated CEA concentrations. Ann Nucl Med. 2010;24:395-401.
29. Sarikaya I, Bloomston M, Povoski SP, Zhang J, Hall NC, Knopp MV, et al. FDG-PET scan in patients with clinically and/or radiologically suspicious colorectal cancer recurrence but normal CEA. World J Surg Oncol. 2007;7:64.